FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study. PMID 42035994 · Am J Transplant · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Continuous Theta-Burst Stimulation on Postoperative Delirium in Older Patients Who Undergo Cardiac Surgery. PMID 42033441 · Neuromodulation · 2026-Apr-24 The study is a randomized trial in humans with a primary result, but it is not oncology, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25). PMID 42033030 · J Natl Cancer Inst · 2026-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial. PMID 42031476 · BMJ Open · 2026-Apr-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial. PMID 42029635 · Clin Cancer Res · 2026-Apr-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study). PMID 42026662 · Cardiovasc Diabetol Endocrinol Rep · 2026-Apr-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer. PMID 41619866 · J Ethnopharmacol · 2026-Apr-24 The record describes a randomized, placebo-controlled clinical trial in advanced colorectal cancer with time-to-event endpoints (PFS, OS). However, the provided metadata does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, the eligibility criterion cannot be fully established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Weifuchun inhibits gastric cancer metastasis by inhibiting angiogenesis mediated by the miR-139-5p/CXCR4 axis. PMID 41577154 · J Ethnopharmacol · 2026-Apr-24 The study is a randomized trial with a drug intervention and reports a time-to-event efficacy endpoint (DFS) for gastric cancer. However, the phase of the trial (e.g., Phase III/IIIb or II/III) is not explicitly established in the provided title, abstract, metadata, or deterministic review signals. The deterministic review flagged 'phase3_evidence_unclear'. Therefore, the 'phase3_or_definitive' criterion cannot be confirmed, making the study ineligible under the strict criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial]. PMID 42086522 · Zhonghua Zhong Liu Za Zhi · 2026-Apr-23 The study is an oncology randomized trial with a drug intervention and reports overall survival, but the explicit trial phase is not provided in the metadata or abstract. The primary efficacy endpoint is a continuous measure (hemoglobin change), not a time-to-event endpoint. The time-to-event component (overall survival) is reported as a secondary endpoint with no statistically significant difference, but the absence of a primary/key secondary time-to-event endpoint (like OS or PFS) as the main focus for digitization makes it ineligible for this specific cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. PMID 42019019 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. PMID 42019018 · N Engl J Med · 2026-Apr-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of a Modular App-Based Pelvic Floor Muscle Training Program for Postoperative Continence Recovery After Radical Prostatectomy: A Multi-Center Randomized Controlled Trial (PELVINTENSE Study). PMID 42122130 · Cancers (Basel) · 2026-Apr-22 The study is an oncology randomized controlled trial reporting primary results, but it evaluates a non-drug intervention (app-based pelvic floor muscle training) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is continence at 90 days (a binary outcome), not a time-to-event measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026. PMID 42025515 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42025514 · Eur Urol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hybrid robot-assisted surgery versus conventional fully robotic surgery for colon cancer: study protocol for a multicenter, parallel-group, single-blind randomized controlled superiority trial. PMID 42021265 · BMC Surg · 2026-Apr-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review. PMID 42018029 · J Neurol · 2026-Apr-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial. PMID 42017206 · Clin Infect Dis · 2026-Apr-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Venous thromboembolism and bleeding in cancer patients: role of inflammatory and cardiac biomarkers. PMID 41384379 · Eur Heart J · 2026-Apr-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Topical Glucocorticosteroids for Proactive Therapy of Acute Radiation-Induced Skin Injury in Head and Neck Cancer: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. PMID 42072482 · Biomedicines · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Endometriosis-Associated Pain: A Systematic Review and Meta-Analysis. PMID 42025872 · J Minim Invasive Gynecol · 2026-Apr-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. PMID 42020286 · Eur Urol Oncol · 2026-Apr-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial. PMID 42020258 · Eur Urol · 2026-Apr-21 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 42020257 · Eur Urol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A diagnostic randomized controlled trial to validate novel dried blood spot (DBS) based technology for prognosis and screening of leukemia transcripts: study protocol. PMID 42015297 · Trials · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| NEO-HYPORT: does neoadjuvant radiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT). PMID 42015277 · Trials · 2026-Apr-21 The record describes a protocol for a randomized trial comparing neoadjuvant vs adjuvant radiotherapy (a non-drug intervention). It is not a report of original trial results with a drug intervention and a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial. PMID 42014146 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial. PMID 42014145 · BMJ Open · 2026-Apr-21 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Correction: Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). PMID 42014130 · BMJ · 2026-Apr-21 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival. PMID 42012774 · Int Urol Nephrol · 2026-Apr-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Study protocol, increasing awareness and early detection in students at risk of gynaecological cancer: feasibility of an online educational and behaviour change intervention. PMID 42010640 · Pilot Feasibility Stud · 2026-Apr-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Gonadotropin-releasing hormone agonist plus aromatase inhibitor versus oral progestins for fertility-sparing treatment in early endometrial carcinoma and atypical hyperplasia: interim analysis of a prospective controlled trial. PMID 42330749 · Int J Gynecol Cancer · 2026-Apr-20 This is an interim report of a prospective randomized controlled trial in oncology (early endometrial carcinoma/atypical hyperplasia) with a drug-containing intervention (GnRH agonist + aromatase inhibitor vs. progestins). However, it is not a Phase III/IIIb or Phase II/III definitive trial (phase is not specified as such, and the interim nature suggests it may be a smaller or earlier-phase study). More critically, the primary endpoint is complete response rate (a binary outcome), not a pre-specified time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or an endpoint reported via Kaplan-Meier/HR). Recurrence rates are mentioned but not as a primary/key secondary time-to-event endpoint with KM/HR. Therefore, it does not meet the core eligibility criteria for a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies. PMID 42074928 · J Clin Med · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reporting of dog-assisted intervention trials: extension of the SPIRIT 2025 and CONSORT 2025 statement. PMID 42010497 · BMC Med Res Methodol · 2026-Apr-20 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial. PMID 42002818 · Trials · 2026-Apr-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. PMID 41774886 · J Clin Oncol · 2026-Apr-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. PMID 41747202 · J Clin Oncol · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial. PMID 41863180 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies. PMID 41855648 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness-Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial. PMID 41996463 · J Med Internet Res · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial. PMID 41996041 · J Gastrointest Cancer · 2026-Apr-17 Study is a randomized trial in gastric cancer but is excluded because it does not involve a drug-containing intervention (probiotics are not a drug) and its primary endpoints are postoperative recovery metrics, not oncology time-to-event efficacy outcomes like OS or PFS. Phase is not stated. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intravenous Thrombolysis at Primary Stroke Centers Versus Comprehensive Stroke Centers: Analysis From the AcT Trial. PMID 41992950 · Can J Neurol Sci · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol. PMID 41992146 · BMC Cancer · 2026-Apr-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis. PMID 41991764 · Breast Cancer Res Treat · 2026-Apr-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. PMID 41453117 · Br J Dermatol · 2026-Apr-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. PMID 41991782 · Patient · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. PMID 41985133 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Asundexian for Secondary Stroke Prevention. PMID 41985132 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia. PMID 41363800 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. PMID 42003280 · Cancer · 2026-Apr-15 The study is a Phase 2 randomized trial in oncology patients with a drug intervention, but it does not meet the definitive phase requirement (Phase III/IIIb or Phase II/III) and does not report a time-to-event efficacy endpoint, which are required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. PMID 41986386 · Nat Commun · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |